Pharma Stocks
-
Indian pharma subsidiary eyes growth
Pfizer Ltd, the listed Indian arm of Pfizer Inc., focuses on key therapeutic areas like oncology and vaccines in one…
Read More » -
Aurobindo Pharma Ltd stock (INE406A01037): up 0.43% on NSE
Aurobindo Pharma Ltd shares rose 0.43% to 1,485.10 INR on May 8, 2026, amid Indian pharma firms’ $19.1B US expansion…
Read More » -
Is Regeneron Pharmaceuticals Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the Best Biotech Stocks. On April 23, Reuters reported that the U.S. Food and Drug…
Read More » -
Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?
If you are wondering whether Amylyx Pharmaceuticals at US$14.73 is still offering value after a strong run, it helps to…
Read More » -
Germany’s listed cannabis and specialty pharma play
Medios AG operates as a specialty pharmaceuticals group with a focus on niche and high-value medicines, including cannabis-based products. Medios…
Read More » -
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) is back in focus after first quarter 2026 results showed 10% year over year revenue growth to…
Read More » -
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX)
Royalty Pharma plc recently reported first-quarter 2026 results showing revenue of US$631 million and net income of US$295 million, both…
Read More » -
Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap
Amylyx Pharmaceuticals (NasdaqGS:AMLX) is advancing avexitide through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH). Pivotal Phase III…
Read More » -
Is It Time To Reassess Phibro Animal Health (PAHC) After The Recent Share Price Pullback
Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or…
Read More » -
Is It Too Late To Consider Johnson & Johnson (JNJ) After A 46.9% One Year Rally?
Wondering if Johnson & Johnson at around US$222 per share offers good value today, or if most of the opportunity…
Read More »